Suppr超能文献

[干细胞疗法治疗克罗恩病复杂性肛瘘:当前证据与未来展望]

[Stem Cell Therapy for Complex Anal Fistula in Crohn`s Disease: Current Evidence and Future Perspectives].

作者信息

Schwandner Oliver

机构信息

Abteilung für Proktologie, Krankenhaus Barmherzige Brüder, Regensburg, Deutschland.

出版信息

Zentralbl Chir. 2023 Jun;148(3):220-227. doi: 10.1055/a-2063-3673. Epub 2023 Jun 2.

Abstract

Despite progress in multidisciplinary diagnostic and therapeutic strategies, complex anal fistulas associated with Crohn's disease remain a challenge for both medical and surgical management. Conventional surgical techniques such as flap procedures or LIFT are still associated with considerable persistence and recurrence rates. Based on this background, results of stem cell therapy for Crohn's anal fistula have shown promising results and are a sphincter-preserving technique. In particular, adipose-derived, allogeneic stem cell therapy (Darvadstrocel) has shown encouraging healing rates within the randomised controlled ADMIRE-CD trial, which were reproducible in "real world" data of limited clinical studies. The current evidence has led to the integration of allogeneic stem cell therapy into international guidelines. To date, the definitive status of allogeneic stem cells in the multidisciplinary treatment algorithm for complex anal fistulas associated with Crohn's disease cannot be evaluated.

摘要

尽管在多学科诊断和治疗策略方面取得了进展,但与克罗恩病相关的复杂性肛瘘仍然是医学和外科治疗的一大挑战。传统的外科技术,如皮瓣手术或括约肌间瘘管结扎术(LIFT),其持续性和复发率仍然相当高。基于这一背景,干细胞疗法治疗克罗恩病肛瘘已显示出有前景的结果,且是一种保留括约肌的技术。特别是,脂肪来源的同种异体干细胞疗法(达沙替尼)在随机对照的ADMIRE-CD试验中显示出令人鼓舞的愈合率,这在有限临床研究的“真实世界”数据中也具有可重复性。目前的证据已促使同种异体干细胞疗法被纳入国际指南。迄今为止,同种异体干细胞在与克罗恩病相关的复杂性肛瘘多学科治疗方案中的最终地位尚无法评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验